

**THE JAMES CROOKS MEMORIAL FELLOWSHIP IN CLINICAL PHARMACOLOGY &
THERAPEUTICS**
Scottish Charity Number: SC052561
Accounts for the year to 31 December 2024


Contents

Report of the Trustees
Report by Independent Examiner
Accounts
Notes to the Accounts
Appendices of Investments

The James Crooks Memorial Fellowship in Clinical Pharmacology & Therapeutics

Report of the Trustees for the year to 31 December 2024

Trustees:



1st Named Trustee for:

Fee Notes /
Contract Notes /
Tax

Date/Manner of Appointment

Position held at Dundee University within
Department in Clinical Pharmacology

Assumed 24.11.2022

Appointment of trustees

Trustees are nominated by the then existing trustees and their appointment confirmed by formal Deed of Assumption.

Trustee Induction and training

The trustees deal appropriately as regards induction and training on any new trustees appointed. This includes awareness of a trustee's responsibilities, the governing document, administrative procedures, and the history and philosophical approach of the charity. A new trustee will receive copies of the previous year's accounts, minutes of recent trustee meetings and a copy of the OSCR booklet "Guidance and good practice for Charity Trustees", if appropriate.


Agents and Administrators for the Trust (and principal address of the Charity)

Thorntons Law LLP, Whitehall House, 33 Yeaman Shore, Dundee DD1 4BJ

Investment Managers


Evelyn Partners, 177 Bothwell Street, Glasgow G2 7ER.

Independent Examiner

 Partner, Henderson Loggie LLP, The Vision Building, 20 Greenmarket, Dundee DD1 4QB

Charity Reference

Scottish Charity No: SC052561


Beneficiaries include all or any one or more of:- (a) The University Department of Pharmacology and Clinical Pharmacology; (b) The Pharmaceutical Industry; (c) Academic Departments of Pharmacology, Clinical Pharmacology and Therapeutics, in particular, but not exclusively, in relation to the award biennially by the University of Dundee upon the recommendation of the Fellowship Trustees of a fellowship in one or more of the following ways:

- By inviting an acknowledged expert in the field of Pharmacology, Clinical Pharmacology or Therapeutics to spend a short period of at least one week in the University Department of Pharmacology and Clinical Pharmacology, during which period the fellow appointed will give a James Crooks memorial Lecture and a series of seminars for staff and postgraduate students;

Report of the Trustees for the year to 31 December 2024 (cont)

- By supporting a young research worker in Clinical Pharmacology or related fields from outwith the University for an extended period of research of up to two months within the University Department of Pharmacology and Clinical Pharmacology; and
- By supporting a member of the University's staff working in Clinical Pharmacology or related fields in undertaking a period of further training in a Department of Clinical Pharmacology either within a University or within the pharmaceutical industry;

Organisation

The day-to-day administration is carried out by Thorntons Law LLP, as agents for the Trust. The trustees meet annually to consider grant applications and to review any other relevant aspects of the Trust's affairs.

Achievements and performance

The trustees have continued their policy of making donations to those charities and institutions as directed in the trust deed.

Risk Management

The trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the trust, and are satisfied that systems are in place to mitigate exposure to those risks. The trustees consider variability of investment returns to constitute the charity's major financial risk. This is mitigated by retaining expert investment managers and having a diversified investment portfolio.

Investment Policy and Performance

There are no restrictions in the Deed on the trustees' power to invest. The policy is, long term, to adopt a medium risk investment strategy, including equity investments, to produce a balance of income and capital growth.

Financial Position

The financial position is as set out on pages 5 and 6.

Reserves Policy

The reserves of the Trust originate from original and subsequent capital bequests, together with the movement in the value of investments, and accumulated revenue. The trustees have adopted a reserves policy that ensures the continuing ability of the Trust to meet its objectives. The level of free reserves held at 31 December 2024 was **£198,666.61** (2023 £197,194.08).

Future Strategy

No changes are presently envisaged in the trust's policies as outlined above.

The James Crooks Memorial Fellowship in Clinical Pharmacology & Therapeutics

Independent Examiner's Report to the trustees of The James Crooks Memorial Fellowship in Clinical Pharmacology & Therapeutics

I report on the accounts of the charity for the period ended 31 December 2024 which are set out on pages 5 to 9.

This report is made to the trustees, as a body, in accordance with the terms of my engagement. My work has been undertaken to enable me to report my opinion set out below and for no other purpose. To the fullest extent permitted by law I do not accept or assume responsibility to anyone other than the trustees, as a body, for my work or for this report.

Respective responsibilities of trustees and examiner

The trustees are responsible for the preparation of the accounts in accordance with the terms of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2005 (as amended). The trustees consider that the audit requirement of Regulation 10(1) (a) to (c) of the 2006 Accounts Regulations does not apply. It is my responsibility to examine the accounts as required under section 44(1) (c) of the Act and to state whether particular matters have come to my attention.

Basis of independent examiner's statement

My examination is carried out in accordance with regulation 11 of the 2006 Accounts Regulations. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeks explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently I do not express an audit opinion on the view given by the accounts.

Independent examiner's statement

In the course of my examination, no matter has come to my attention:

1. which gives me reasonable cause to believe that in any material respect the requirements:
 - to keep accounting records in accordance with section 44(1) (a) of the 2005 Act and Regulation 4 of the 2006 Accounts Regulations, and
 - to prepare accounts which accord with the accounting records and comply with Regulation 8 of the 2006 Accounts Regulationshave not been met, or;
2. to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



Partner
For and on behalf of Henderson Loggie LLP
The Vision Building
20 Greenmarket
Dundee
DD1 4QB

23 September 2025

The James Crooks Memorial Fellowship in Clinical Pharmacology & Therapeutics

Receipts and Payments Account for the year ended 31 December 2024

	<i>Schedule/ Appendix</i>	2024 £	2023 £
Receipts			
Investment income	<i>Sch 1</i>	3,866.51	2,798.36
Sale proceeds from investments	<i>App 2</i>	<u>115,624.34</u>	<u>108,730.93</u>
Total receipts		<u>119,490.85</u>	<u>111,529.29</u>
Payments			
Charitable activities	<i>Sch 2</i>	4,700.00	2,310.00
Governance	<i>Sch 3</i>	4,141.68	3,484.16
Cost of generating funds	<i>Sch 4</i>	907.87	-
Purchase of Investments	<i>App 2</i>	<u>113,008.06</u>	<u>114,166.62</u>
Total payments		<u>122,757.61</u>	<u>119,960.78</u>
Deficit for the year		<u>(3,266.76)</u>	<u>(8,431.49)</u>

All funds are unrestricted.

The James Crooks Memorial Fellowship in Clinical Pharmacology & Therapeutics

Statement of Balances as at 31 December 2024

	<i>Schedule/ Appendix</i>	2024 £	2023 £
Cash on deposit and on hand			
Opening balance		6,579.08	-
Funds transferred to Charity		-	15,010.57
Deficit for the year		(3,266.76)	(8,431.49)
Closing balance		3,312.32	6,579.08
Reserves			
Unrestricted Funds		3,312.32	6,579.08
Investments			
As valued at 31.12.24	<i>App 3</i>	200,154	194,035
Estimated Liabilities as at 31.12.24			
Thorntons Law LLP, administration fees		3,120.00	2,400.00
Evelyn Partners, portfolio management fees		557.71	-
Independent Examiner Fee		1,122.00	1,020.00
		4,799.71	3,420.00

The James Crooks Memorial Fellowship in Clinical Pharmacology & Therapeutics

Schedule 1	2024	2023
Income received	£	£
Dividends and interest, per Appendix 1	3,866.51	2,798.36

Schedule 2 **Charitable Activities**

Distributions made in year (£500 each to 4 individuals)	2,000.00	-
Support costs (Schedule 3)	2,700.00	2,310.00
	4,700.00	2,310.00

Schedule 3 **Support costs**

	Governance	Charitable	2024
	£	Activities	Total
		£	£
Thorntons, their fee for Trust administration, commissions, posts etc. for the period to 31.12.24 (inc VAT)	2,700.00	2,700.00	5,400.00
Henderson Loggie – independent examination of the 2023 Accounts	1,020.00	-	1,020.00
Renewal Advisory Remuneration – [REDACTED]	300.63	-	300.63
Custody Charges	121.05	-	-
	4,141.68	2,700.00	6,841.68

Schedule 3	Governance	Charitable	2023
Support costs	£	Activities	Total
		£	£
Thorntons, their fee for Trust administration, commissions, posts etc. for the period to 31.12.23 (inc VAT)	2,310.00	2,310.00	4,620.00
Renewal Advisory Remuneration – [REDACTED]	1,008.07	-	1,008.07
Custody Charges	166.09	-	166.09
	3,484.16	2,310.00	5,794.16

No Trustees received any remuneration or expenses from the Trust during this or the preceding year.

The Trust has no employees.

The James Crooks Memorial Fellowship in Clinical Pharmacology & Therapeutics

Schedule 4

Cost of generating funds

	2024	2023
	£	£
Evelyn Partners, portfolio management fees	907.87	-

Schedule 5

Statement of Revenue balance as at 31.12.24

	2024	2023
	£	£
Income received in the year	3,883.20	2,798.36
Distributions paid to beneficiaries	(2,000.00)	-
Support costs	(2,700.00)	(3,484.16)
	(816.80)	(685.80)
Balance as at 31.12.23	(685.80)	-
Balance as at 31.12.24	(1,502.60)	(685.80)

Notes to the Accounts and General Notes regarding the Financial Services and Markets Act 2000, Law Society Rules and related matters***Basis of Preparation***

The Accounts are prepared in accordance with the Charities Accounts (Scotland) Regulations 2006 (as amended).

Investments etc

In these Accounts stocks and shares, gilts, debentures and warrants are valued at their Stock Market value, if listed on a registered Stock Exchange, or otherwise at either (i) the latest available valuation known to us or (ii) cost, at our discretion. Unit Trusts are valued at their approximate bid price. Life Assurance policies are not valued.

Realised gains or losses are transferred to Capital. Unrealised appreciation or depreciation in the value of investments - as compared to their CGT base costs - is dealt with under "Adjustment on revaluation/rebasing".

Contract Notes

In terms of our Law Society Rules we are required to forward copies of all Contract Notes relating to the sale or purchase of investments to clients. In the case of Trusts we fulfil this requirement by forwarding a copy to the first named independent Trustee (i.e. a Trustee who is not a partner/nominee company of our firm) based on the order of Trustees set out on the first page of the Trust Accounts, unless otherwise agreed.

Stockbroker Commissions

As reimbursement of stockbroker commissions received on the purchase or sale of stocks and shares is administratively expensive and as the amounts involved are normally fairly minor, our practice is *not* to reimburse such commissions to the Trust, but to take them into account in the overall assessment of our fees. Any commissions received through Thorntons Investment Managers are retained in full unless otherwise agreed.

Investment Managers

The Trustees approve the continued appointment of the Investment Managers as detailed in the General Information section in these Accounts, and on the same basis as contained in the Investment and Financial Services Terms of Business Agreement currently in force.

Nomineeship:

The trustees approve the appointment of the nominee company as detailed in the General Information section in these Accounts to continue to hold certain or all of the investments owned by the trustees, and that on the same basis as contained in the Investment and Financial Services Terms of Business Agreement currently in force.

Independent Examiner

The trustees approve the continued appointment of the Independent Examiner as detailed in the Report of the trustees in these Accounts.

Going Concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the Trust has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

The James Crooks Memorial Fellowship in Clinical Pharmacology and TherapeuticsAppendix 1Accounts for the period ended 31 December 2024

Dividends & Interest received in the period ended 31 December 2024

	£
05/01/2024 J P MORGAN GLOBAL GROWTH & INCOME P ORD GBP0.05	125.66
12/01/2024 Fund Cash Rebate November 23	0.36
18/01/2024 FIDELITY GLOBAL DIVIDEND W INC	78.09
31/01/2024 TB EVENLODE INVESTMENT FUNDS ICVC TB EVENLODE INCOME F	77.69
09/02/2024 Fund Cash Rebate December 23	0.38
23/02/2024 OCTOPUS RENEWABLES INFRASTRUCTURE	180.12
28/02/2024 RATHBONE UNIT TRUST MANAGEMENT LTD RATHBONE ETHICAL BO	138.63
13/03/2024 Fund Cash Rebate January 2024	0.38
28/03/2024 IFSL MARLBOROUGH NO 2 OEIC IFSL MARLBOROUGH MULTI CAP	154.84
28/03/2024 VONTOBEL FUND TWENTYFOUR SHORT TERM BOND	180.96
31/03/2024 BAILLIE GIFFORD UK & BAL FDS ICVC	93.80
15/04/2024 Fund Cash Rebate February 2024	0.15
16/04/2024 JPMORGAN GROWTH & INCOME ORD 5P	125.67
18/04/2024 FIDELITY INV FDS GLOBAL DIVIDEND FUND	127.26
22/04/2024 UK GOVT 3.5% 22/10/25	157.45
30/04/2024 TB EVENLODE INVESTMENT FUNDS ICVC TB EVENLODE INCOME F	109.99
17/05/2024 FINSBURY GROWTH & INCOME TRUST ORD 25P	120.30
20/05/2024 FIDELITY GLOBAL DIVIDEND INC	27.83
31/05/2024 RATHBONE UNIT TRUST MANAGEMENT LTD RATHBONE ETHICAL BO	143.96
18/06/2024 FIDELITY GLOBAL DIVIDEND INC	27.83
28/06/2024 VONTOBEL FUND TWENTYFOUR SHORT TERM BOND	76.27
01/07/2024 BAILLIE GIFFORD UK & BAL FDS ICVC	75.76
03/07/2024 JPMORGAN GROWTH & INCOME ORD 5P	125.67
18/07/2024 FIDELITY GLOBAL DIVIDEND INC	27.83
30/07/2024 UK GOVT 0.125% 30/01/26	6.05
31/07/2024 UK GOVT 3.25% 31/01/33	153.76
31/07/2024 ARTEMIS INV FUNDS CORPORATE BOND	47.47
01/08/2024 TB EVENLODE INVESTMENT FUNDS ICVC TB EVENLODE INCOME F	80.49
09/08/2024 BNY MELLON GLOBAL FUNDS US EQUITY INCOME	20.63
19/08/2024 FIDELITY GLOBAL DIVIDEND INC	27.83
09/09/2024 UK GOVT 3.75% 07/03/27	222.54
18/09/2024 FIDELITY GLOBAL DIVIDEND INC	27.83
26/09/2024 JPMORGAN GLOBAL OPPS SUST	0.01
30/09/2024 VONTOBEL FUND TWENTYFOUR SHORT TERM BOND	82.26
30/09/2024 BAILLIE GIFFORD UK & BAL FDS ICVC	74.86
07/10/2024 JPMORGAN GROWTH & INCOME ORD 5P	155.38
18/10/2024 FIDELITY GLOBAL DIVIDEND INC	27.83
22/10/2024 UK GOVT 3.5% 22/10/25	157.45
31/10/2024 TB EVENLODE INVESTMENT FUNDS ICVC TB EVENLODE INCOME F	80.49
31/10/2024 ARTEMIS INV FUNDS CORPORATE BOND	98.12
08/11/2024 BNY MELLON GLOBAL FUNDS US EQUITY INCOME	41.56
08/11/2024 FINSBURY GROWTH & INCOME TRUST ORD 25P	109.40
18/11/2024 FIDELITY GLOBAL DIVIDEND INC	27.83
18/12/2024 FIDELITY GLOBAL DIVIDEND INC	27.83
31/12/2024 VONTOBEL FUND TWENTYFOUR SHORT TERM BOND	87.49
31/12/2024 BAILLIE GIFFORD UK & BAL FDS ICVC	74.86
	3,808.85
Interest received for the period to 31 December 2024	57.66
	3,866.51

The James Crooks Memorial Fellowship in Clinical Pharmacology and Therapeutics

Appendix 2

Accounts for the period ended 31 December 2024

Investment sales and purchases for the period ended 31 December 2024

	Units	Investment	£
Sales			
05/04/2024	12,422	OCTOPUS RENEWABLES INFRA TR PLC ORD GBP0.01	8,803.12
08/04/2024	13,330.07	RATHBONE UNIT TRUST MANAGEMENT LTD RATHBONE ETHICAL BOND I DIS	11,371.88
08/04/2024	6,193.724	IFSL MARLBOROUGH MULTI CAP INCOME P DIS	8,254.38
08/04/2024	81.222	VONTOBEL TWENTYFOUR SHORT TERM BOND	7,607.25
08/04/2024	149.41	JPMORGAN GLOBAL BD OPPS	13,923.52
30/07/2024	451	XTRACKERS PHYSICAL GOLD	5,581.35
30/07/2024	354	FINSBURY GROWTH & INCOME ORD 25P	2,993.21
31/07/2024	2,163.3	INVESCO EUROPEAN INV EUROPEAN EQUITY UK Z	10,707.25
31/07/2024	5,365.659	HERIOT INV FUNDS GLOBAL A ACC	16,847.63
31/07/2024	38.6538	TM FULCRUM DIVERSIFIED ABST RETURN ACC	5,827.45
31/07/2024	119.82	TRIUM UCITS PLATFORM EMISSIONS IMPROVERS ACC	15,219.54
31/07/2024	0	ARTEMIS INV FUNDS CORP BOND - equalisation	49.71
09/08/2024	0	BNY MELLON GLOBAL FDS US EQUITY INC - equalisation	22.05
04/11/2024	352	JPMORGAN GLOBAL GROWTH & INCOME ORD 5P	2,003.79
05/11/2024	2,515	FIDELITY GLOBAL DIVIDEND INC	2,987.82
08/11/2024	0	BNY MELLON GLOBAL FDS US EQUITY INC - equalisation	6.41
18/12/2024	2,628	LIONTRUST EUROPEAN DYNM ACC	3,417.98
			115,624.34
Purchases			
05/04/2024	8,997	UK GOVT 3.5% BDS 22/10/25	9,000.88
05/04/2024	9,076	UK GOVT 3.75% BDS 07/03/27	9,043.87
05/04/2024	9,462	UK GOVT 3.25% BDS 31/01/33	8,993.74
05/04/2024	9,680	UK GOVT 0.125% BDS 30/01/26	8,998.69
08/04/2024	7,612.005	ARTEMIS INV FUNDS CORP BOND	6,967.27
08/04/2024	4,160.475	BNY MELLON GLOBAL FDS US EQUITY INC	6,960.06
30/07/2024	301	XTRACKERS PHYSICAL GOLD	8,506.20
30/07/2024	135.341	DODGE & COX WORLDWIDE US STOCK	8,000.01
30/07/2024	263.84	GUINNESS ASSET MANAGEMENT GLOBAL EQUITY INCOME Z	8,000.05
31/07/2024	4,923.869	LIONTRUST PARTNERS EUROPEAN DYNM ACC	6,500.00
31/07/2024	53.97	NATIXIS INTERNATIONAL GROWTH EQUITY	9,000.04
31/07/2024	69.94	TRIUM UCITS PLATFORM CLIMATE IMPACT ACC	6,999.60
31/07/2024	1,780.838	BNY MELLON GLOBAL FDS US EQUITY INC	3,000.00
01/08/2024	66.5583	MONTLAKE UCITS MYGALE EVENT DRIVEN	7,000.00
15/10/2024	1,094	ARTEMIS INV FUNDS CORP BOND	1,004.07
15/10/2024	6	NATIXIS INTERNATIONAL GROWTH EQUITY	1,060.68
18/12/2024	850	PREMIER MITON INVESTMENT FUNDS US OPPS ACC	3,972.90
			113,008.06

Portfolio Valuation

Account Group Name - The James Crook Memorial Fellowship

Investment	Units / Shares	Book Cost £	Price	Value £	% of Total Portfolio	Gain / (Loss) £	Estimated Income £	Estimated Yield %	Account Code
Government Fixed Income									
Sovereign Debt									
UK GOVT OF 0.125% 16/01/2026 GBP 1000	9.680	8.989	£0.9603	9,295.71	4.6	297	17	0.1	AW 7595 DIM O1
Excludes 154 days accrued interest of £5.09									
UK GOVT OF 1.25% 31/01/2033 GBP 1000	9.402	8.994	£0.9167	8,614.29	4.4	319	308	3.5	AW 7595 DIM O1
Excludes 153 days accrued interest of £129.55									
UK GOVT OF 3.5% 22/10/2025 GBP 1001	8.997	9.001	£0.9918	8,922.77	4.4	78	315	3.5	AW 7595 DIM O1
Excludes 76 days accrued interest of £60.23									
UK GOVT OF 3.75% 07/03/2027 GBP 1000	9.076	9.044	£0.9671	8,958.92	4.5	185	340	3.8	AW 7595 DIM O1
Excludes 115 days accrued interest of £108.94									
Investment Grade Corporate Bonds									
Investment Grade Collectives									
INVESTMENT GRADE SUSTAINABLE SHORT TERM BOND INCOME A03 LP9	74.779	6.980	£94.32	7,053.16	3.5	173	333	4.7	AW 7595 DIM O1
Investment Grade									
ARTEM'S CORPORATE BUNDE GBP DIS	7.966108	7.522	£0.9974	7,945.40	3.9	24	410	5.2	AW 7595 DIM O1
Equity									
UK Collectives									
PINNEY GROWTH & INCOME TRUST ORD CDP0 25	1.013	8.644	£8.95	9,066.35	4.5	422	199	2.2	AW 7595 DIM O1
+ SLE/REAL GDP INCOME LINK	4.590585	11.285	£2.62	12,001.13	5.9	716	351	2.9	AW 7595 DIM O1
North America Collectives									
BNY MFLN US B FDS PRY MFLN US FGINC F GBP	5.941313	9.939	£1.7839	10,594.59	5.2	663	213	2.0	AW 7595 DIM O1
DOUGLAS & COA ACQUADIVIDE US STO 30 GBP ACC	135.341	8.507	£61.56	8,331.50	4.1	230	0	0.0	AW 7595 DIM O1
LF MITALUS EQUITY IN TIES F ACC	860	3.970	£4.59	3,876.06	1.9	197	9	0.2	AW 7595 DIM O1
Europe Collectives									
JOHN FOSTER EUROPEAN DYNAMIC S 26P ACC	2.235866	3.031	£1.2070	2,955.47	1.5	179	56	1.9	AW 7595 DIM O1

From 1 January 2024 to 31 December 2024

Portfolio report | 10

Portfolio Valuation

Investment	Units / Shares	Book Cost £	Price	Value £	% of Total Portfolio	Gain / (Loss) £	Estimated Income £	Estimated Yield %	Account Code
Asia Pacific Collectives									
STEWART INVESTORS ASIA PACIFIC SUSTAINABILITY B ACC	731022	5.068	£8.9869	6,569.62	3.2	701	34	0.5	AW 7595 DIM 01
Emerging Markets Collectives									
SCOTIA INVESTMENT FUND MANAGERS EMERGING MARKET EQUITY A USD	3,808,647	4.064	£18.118	5,908.09	2.7	1,444	0	0.0	AW 7595 DIM 01
Global Collectives									
BALLET GIFFORD RESPONSIBLE GLOBAL EQUITY INCOME W6 INC	9,019,253	13.539	£1.693	15,269.60	7.5	1,730	318	2.1	AW 7595 DIM 01
FIDELITY GLOBAL DIVIDEND # INC	9,177,64	9.098	£1.183	10,857.15	5.4	1,759	262	2.4	AW 7595 DIM 01
GUINNESS GLOBAL EQUITY INCOME 2 GBP INC	263,84	8.000	£31.861	8,406.21	4.2	406	173	2.0	AW 7595 DIM 01
JPMORGAN GLOBAL GROWTH & INCOME PLC ORD GBP 0.05	2,374	11.006	£5.81	13,792.94	6.8	2,787	541	3.9	AW 7595 DIM 01
SATIXIS INTL (LUX) LOOMIS SAVILES GLOBAL GROWTH EQUITY S2A GBP	59.97	10.061	£192.26	11,529.83	5.7	1,469	0	0.0	AW 7595 DIM 01
Commodity									
Collectives									
XIE PHYSICAL GOLD ETC GBP	301	8.506	£30.73	9,249.73	4.6	744	0	0.0	AW 7595 DIM 01
Absolute Return									
Global Collectives									
TRIUM CAPITAL MANAGEMENT LTD GBP	69.94	7.000	£98.87	6,914.97	3.4	(85)	0	0.0	AW 7595 DIM 01
Collectives									
FULCRUM DIVERSIFIED ABSOLUTE RETURN C GBP ACC	46,617	6.412	£154.35	7,195.33	3.6	784	30	0.4	AW 7595 DIM 01
MYGAL EVENT DRIVEN MULTI-H INSTL POOL GBP	66,5583	7.000	£107.9514	7,185.06	3.6	185	0	0.0	AW 7595 DIM 01
Cash									
Cash									
Investment Account GBP	1,832.32	1.832	£1	1,832.32	0.9	0	30	1.6	AW 7595 DIM 01
Portfolio Totals									
				201,986.19	100.0	13,887	3,933	1.9	
Accrued Interest				300.81					
Total (Including Accrued Interest)				202,287.00					

201,986.19
(1,832.32)
200,153.87